Retrospective Study
Copyright ©The Author(s) 2024.
World J Psychiatry. Jul 19, 2024; 14(7): 1017-1026
Published online Jul 19, 2024. doi: 10.5498/wjp.v14.i7.1017
Table 1 Demographic and clinical characteristics of study-eligible patients
Characteristics
Eligible, n = 62
Sex
    Male29
    Female33
Age in years
    ≤ 6549
    > 6513
Education
    High school or less23
    College20
    Bachelor’s degree15
    Graduate degree4
ECOG performance status
    < 28
    ≥ 27
BMI in kg/m2, median (IQR)25.4 (22.2-28.7)
High serum LDH9
High serum β2m11
Table 2 Psychological symptom scores in patients with diffuse large B-cell lymphoma during chemotherapy
Item
Eligible, n = 62
Score
Restless sleep58 (93.55)4.51 ± 1.38
Sadness57 (91.94)4.77 ± 1.40
Forgetfulness50 (80.65)3.48 ± 1.12
Distress58 (93.55)4.53 ± 1.37
Numbness30 (48.39)3.47 ± 1.08
Table 3 Pittsburgh Sleep Quality Index and Five-Facet Mindfulness Questionnaire-Short Form of patients with diffuse large B-cell lymphoma during chemotherapy
Assessment measure
Scores
PSQI10.49 ± 1.28
FFMQ-SF49.85 ± 10.67
Table 4 Cancer-related fatigue status of patients with diffuse large B-cell lymphoma, n = 62
Dimension
Average score
Mild fatigue, n (%)
Moderate fatigue, n (%)
Severe fatigue, n (%)
Behavior fatigue6.57 ± 2.4318 (29.03)35 (56.45)9 (14.52)
Emotional fatigue5.25 ± 2.1415 (24.19)29 (46.78)34 (29.03)
Perceived fatigue6.39 ± 2.3620 (32.26)32 (51.61)10 (16.13)
Cognitive fatigue5.37 ± 2.4825 (40.32)21 (33.87)16 (25.81)
Total CRF score 5.74 ± 2.5124 (38.71)26 (41.94)12 (19.35)
Table 5 Univariate analysis of cancer-related fatigue in patients with diffuse large B-cell lymphoma
Influencing factors
Eligible, n = 62
Average PFS score
P value
Sex0.543
    Male295.44 ± 2.32
    Female335.74 ± 2.20
Age in years0.095
    ≤ 65494.59 ± 1.25
    > 65135.15 ± 2.42
Marital status0.206
    Married215.57 ± 2.34
    Unmarried405.95 ± 2.53
    Others16.54 ± 2.32
Education0.390
    High school or less234.39 ± 1.60
    College204.37 ± 1.38
    Bachelor’s degree155.07 ± 2.21
    Graduate degree45.93 ± 2.52
Self-efficacy level260.031
    High264.66 ± 1.71
    Medium95.56 ± 2.30
    Low5.90 ± 2.51
Anxiety and depression degree0.033
    Mild204.72 ± 1.32
    Moderate295.50 ± 2.53
    Severe135.97 ± 2.85
Tumor staging0.001
    Stage I254.34 ± 1.55
    Stage II145.64 ± 2.19
    Stage III135.82 ± 2.44
    Stage IV106.78 ± 3.13
Chemotherapy cycle0.006
    First cycle234.09 ± 1.13
    Second cycle194.52 ± 1.40
    Third cycle115.72 ± 2.37
    Fourth cycle96.46 ± 3.50
Pain degree0.004
    Mild154.54 ± 1.75
    Moderate375.48 ± 2.44
    Severe106.31 ± 3.47
Table 6 Cancer-related fatigue-related symptoms during chemotherapy in the study patients
Items
Eligible, n = 62
Score
Fatigue59 (95.16)4.48 ± 1.47
Pain51 (82.26)4.42 ± 1.48
Dry mouth55 (88.71)4.35 ± 1.32
Lethargy54 (87.10)4.08 ± 1.34
Shortness of breath28 (45.16)3.52 ± 1.16
Table 7 Perceptual control scores in patients with diffuse large B-cell lymphoma during chemotherapy
Items
Score
Cancer experience
    Personal experience13.71 ± 1.98
    Social experience24.01 ± 3.02
    Emotional experience21.51 ± 3.12
Cancer efficacy
    Personal efficacy15.71 ± 4.66
    Collective efficacy18.28 ± 4.72
    Medical care efficacy11.63 ± 2.03
Table 8 Factors influencing cancer-related fatigue in patients with diffuse large B-cell lymphoma during chemotherapy
Factor
Regression coefficient
Wald χ2 value
P value
OR
Tumor staging0.4595.4400.0151.583
Chemotherapy cycle0.2334.6290.0031.339
Self-efficacy level0.5598.4290.0041.274
Anxiety and depression level0.4608.3400.0011.674